Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice

Terpos, Evangelos; Katodritou, Eirini; de la Rubia, Javier; Hungria, Vania; Hulin, Cyrille; Roussou, Maria; Delforge, Michel; Bries, Greet; Stoppa, Anne-Marie; Aagesen, Jesper; Sargin, Deniz; Belch, Andrew; Ahlberg, Lucia; Diels, Joris; Olie, Robert; Robinson, Don; Spencer, Mike; Potamianou, Anna; van de Velde, Helgi; Dimopoulos, Meletios

doi:10.1111/ejh.13147

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice

Atıf İçin Kopyala

Terpos E., Katodritou E., de la Rubia J., Hungria V., Hulin C., Roussou M., ...Daha Fazla

EUROPEAN JOURNAL OF HAEMATOLOGY, cilt.101, sa.4, ss.556-565, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 101 Sayı: 4
Basım Tarihi: 2018
Doi Numarası: 10.1111/ejh.13147
Dergi Adı: EUROPEAN JOURNAL OF HAEMATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.556-565
İstanbul Üniversitesi Adresli: Evet

Özet

Objective: The efficacy and safety of bortezomib-based therapy for relapsed/refractory multiple myeloma (RRMM) in clinical trials may differ from the oncology practice experience. The electronic VELCADE (R) OBservational Study was designed to prospectively evaluate bortezomib for multiple myeloma (MM) in real-world medical practice.